UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 428

Sortiert nach

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2055-2062

2012

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2046-2054

2012

Link zum Volltext

Verfügbarkeit prüfen

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Journal of clinical oncology, 2010-10, Vol.28 (30), p.4594-4600

2010

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

The lancet oncology, 2014-02, Vol.15 (2), p.143-155

2014

Link zum Volltext

Verfügbarkeit prüfen

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Journal of clinical oncology, 2012-03, Vol.30 (9), p.921-929

2012

Link zum Volltext

Verfügbarkeit prüfen

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

JNCI : Journal of the National Cancer Institute, 2014-01, Vol.106 (1), p.djt337-djt337

2014

Link zum Volltext

Verfügbarkeit prüfen

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of clinical oncology, 2009-02, Vol.27 (5), p.663-671

2009

Link zum Volltext

Verfügbarkeit prüfen

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Journal of clinical oncology, 2013-10, Vol.31 (30), p.3791-3799

2013

Link zum Volltext

Verfügbarkeit prüfen

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1252-1260

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Breast cancer research : BCR, 2016-06, Vol.18 (1), p.67-67, Article 67

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Journal of clinical oncology, 2013-01, Vol.31 (2), p.195-202

2013

Link zum Volltext

Verfügbarkeit prüfen

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

The lancet oncology, 2011-08, Vol.12 (8), p.795-805

2011

Link zum Volltext

Verfügbarkeit prüfen

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

Journal of clinical oncology, 2012-10, Vol.30 (29), p.3588-3595

2012

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the Mathematical Model of Open Coaxial Measuring Microwave Converters

Mobile networks and applications, 2020-08, Vol.25 (4), p.1582-1586

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

British journal of haematology, 2018-08, Vol.182 (4), p.583-586

2018

Link zum Volltext

Verfügbarkeit prüfen

A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

The oncologist (Dayton, Ohio), 2016-01, Vol.21 (1), p.7-15

2016

Link zum Volltext

Verfügbarkeit prüfen

ON THE EXCITATION OF LOCAL ELECTRIC CURRENT IN THE BIOLOGICAL ENVIRONMENT

Sučasnij stan naukovih doslìdženʹ ta tehnologìj v promislovostì (Online), 2021-03 (1 (15)), p.106-112

2021

Link zum Volltext

Verfügbarkeit prüfen

CHPC: A complex semantic-based secured approach to heritage preservation and secure IoT-based museum processes

Computer communications, 2019-12, Vol.148, p.240-249

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-07, Vol.35 (4), p.417-428

2021

Link zum Volltext

Verfügbarkeit prüfen

Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial

Journal of clinical oncology, 2013-04, Vol.31 (10), p.1341-1347

2013

Link zum Volltext

Verfügbarkeit prüfen

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.4-4

2023

Link zum Volltext

Verfügbarkeit prüfen

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4522-4529

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 428

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(379)
Mit Volltextzugriff
(390)

Publikationsform

Sprache

Englisch
(416)
Russisch
(24)
Japanisch
(10)
Polnisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(186)
Life Sciences & Biomedicine
(134)
Humans
(113)
Oncology
(84)
Female
(79)
Middle Aged
(60)
Aged
(49)
Adult
(48)
Male
(44)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(37)
Double-Blind Method
(37)
Treatment Outcome
(35)
Breast Neoplasms - Drug Therapy
(34)
Chemotherapy
(34)
Technology
(31)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(30)
Disease-Free Survival
(25)
Physical Sciences
(25)
Breast Cancer
(24)
Clinical Trials
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

Analysis of the Mathematical Model of Open Coaxial Measuring Microwave Converters

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

ON THE EXCITATION OF LOCAL ELECTRIC CURRENT IN THE BIOLOGICAL ENVIRONMENT

CHPC: A complex semantic-based secured approach to heritage preservation and secure IoT-based museum processes

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study

Suchergebnisse filtern